Oncolytics Biotech Inc. (ONCY) Sets GOBLET Data Readouts; Final PanCAN Grant Due

Oncolytics Biotech (ONCY) updated its GOBLET study timelines, expecting final PanCAN grant payment in Q4 2026. Cohort 4 data is due in Q4 2026, with Cohort 5 results in H1 2027. Median overall survival in Cohort 4 exceeded expectations, and the company is winding down study infrastructure while monitoring remaining patients. ONCY is developing pelareorep for gastrointestinal cancers and is currently trading at $0.55, up 13.72%.

Oncolytics Biotech (NASDAQ:ONCY) completed enrollment in its GOBLET Phase 1/2 study and expects final grant payment this quarter. Cohort 4 results are due in Q4 2026, with Cohort 5 results in H1 2027. The study, conducted in Germany, focuses on pelareorep-based therapies for cancer. The company plans to use data to guide future strategies. Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

Oncolytics Biotech (ONCY) reported preclinical findings in PNAS showing pelareorep treatment may alter the tumor microenvironment in liver cancer, increasing PD-L1 and ICOSL levels, and CD8+ T-cell density. The company noted liver cancer is not a target indication but is studying pelareorep in colorectal cancer with an interim update expected by year-end 2026. ONCY stock closed at $0.67, down 2.05% in premarket.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype

Oncolytics Biotech (Nasdaq: ONCY) announced data published in the Proceedings of the National Academy of Sciences showing pelareorep can alter the tumor microenvironment in liver cancer, making it susceptible to immunotherapy. The study demonstrated increased PD-L1 expression, ICOSL levels, and CD8+ T cell density. Oncolytics is developing pelareorep for metastatic gastrointestinal cancers and is pursuing strategic partnerships.